Myocardial Infarction Market size was USD 21.7 billion in 2023 to Grow in Coming Years, 2024-2034 Analysis by DelveInsight | Pfizer, Mitsubishi Tanabe Pharma, Bayer, KAI Pharma, Egetis Therapeutics,

The Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the 7MM.
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Myocardial Infarction, offering comprehensive insights into the Myocardial Infarction revenue trends, prevalence, and treatment landscape. The report delves into key Myocardial Infarction statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Myocardial Infarction therapies. Additionally, we cover the landscape of Myocardial Infarction clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Myocardial Infarction treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Myocardial Infarction space.

To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast [https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Myocardial Infarction Market Report:

*
The Myocardial Infarction market size was valued ~USD 21.7 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
Estimates suggest that the United States will represent the largest market for myocardial infarction, with a market size of approximately USD 16.3 billion in 2023, due to a higher number of cases and relatively higher treatment costs.

*
Key Myocardial Infarction Companies: Thrombologic ApS, Honya Medical Inc, Boehringer Ingelheim, KU Leuven, Pfizer, Mesoblast, Inc., Beijing Anzhen Hospital, TargeGen, GlaxoSmithKline, Stiftung Institut fuer Herzinfarktforschung, Novartis, Mitsubishi Tanabe Pharma Corporation, Bayer, KAI Pharmaceuticals, Rambam Health Care Campus, Quantum Genomics SA, Hoffmann-La Roche, Egetis Therapeutics, Stempeutics Research Pvt Ltd, Lantheus Medical Imaging, and others.

*
Key Myocardial Infarction Therapies: Ilomedin, MiSaver Registered , BI 765845, Empagliflozin, Tenecteplase, Eplerenone, Prochymal Registered , Shenfu Injection, TG100-115, Abciximab, Clopidogrel (Iscover/Plavix), Aliskiren, MCC-135, Fulacimstat (BAY1142524), KAI-9803, Atorvastatin, Ramipril, RO4905417, Mangafodipir, Plasmalyte A, Technetium Tc99m Sestamibi, and others.

*
The Myocardial Infarction market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Myocardial Infarction pipeline products will significantly revolutionize the Myocardial Infarction market dynamics.

*
In 2023, the total number of diagnosed prevalent cases of myocardial infarction across the 7MM was around 15.5 million, with projections indicating an increase throughout the forecast period.

*
In 2023, the United States had the largest proportion of myocardial infarction cases, representing approximately 55% of the 7MM total. Meanwhile, the EU4 and the UK together accounted for about 35%, and Japan made up around 10% of the total population share.

*
Within the EU4 and the UK, Germany had the highest number of diagnosed myocardial infarction cases, followed by France, while Spain had the fewest cases in 2023.

*
In 2023, the United States reported approximately 3.2 million cases of STEMI and 5 million cases of NSTEMI. The prevalence is expected to rise over the forecast period.

*
In February 2024, Global biotechnology leader CSL Behring announced the top-line results from the Phase 3 AEGIS-II trial, which evaluated the efficacy and safety of CSL112 (apolipoprotein A-I [human]) compared to placebo in reducing the risk of major adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI). The study did not achieve its primary efficacy endpoint of reducing MACE at 90 days, and as a result, there are no plans for a regulatory filing in the near term. However, no major safety or tolerability issues were observed with CSL112.

Myocardial Infarction Overview

Myocardial Infarction, commonly known as a heart attack, occurs when blood flow to a part of the heart is blocked, leading to damage or death of the heart muscle. This condition is a major medical emergency that requires prompt treatment to restore blood flow and minimize heart damage. Treatment options include medications, such as antiplatelet drugs, beta-blockers, and ACE inhibitors, as well as therapies like angioplasty or coronary artery bypass surgery. Ongoing clinical trials are focused on developing new therapies and improving existing treatments to enhance recovery and reduce the risk of future heart attacks.

Get a Free sample for the Myocardial Infarction Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/myocardial-infarction-market [https://www.delveinsight.com/report-store/myocardial-infarction-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Myocardial Infarction Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Myocardial Infarction Epidemiology Segmentation:

The Myocardial Infarction market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Myocardial Infarction

*
Prevalent Cases of Myocardial Infarction by severity

*
Gender-specific Prevalence of Myocardial Infarction

*
Diagnosed Cases of Episodic and Chronic Myocardial Infarction

Download the report to understand which factors are driving Myocardial Infarction epidemiology trends @ Myocardial Infarction Epidemiology Forecast [https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Myocardial Infarction Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myocardial Infarction market or expected to get launched during the study period. The analysis covers Myocardial Infarction market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Myocardial Infarction Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Myocardial Infarction Therapies and Key Companies

*
Ilomedin: Thrombologic ApS

*
MiSaver Registered : Honya Medical Inc

*
BI 765845: Boehringer Ingelheim

*
Empagliflozin: Boehringer Ingelheim

*
Tenecteplase: KU Leuven

*
Eplerenone: Pfizer

*
Prochymal Registered : Mesoblast, Inc.

*
Shenfu Injection: Beijing Anzhen Hospital

*
TG100-115: TargeGen

*
Abciximab: GlaxoSmithKline

*
Clopidogrel (Iscover/Plavix): Stiftung Institut fuer Herzinfarktforschung

*
Aliskiren: Novartis

*
MCC-135: Mitsubishi Tanabe Pharma Corporation

*
Fulacimstat (BAY1142524): Bayer

*
KAI-9803: KAI Pharmaceuticals

*
Atorvastatin: Rambam Health Care Campus

*
Ramipril: Quantum Genomics SA

*
RO4905417: Hoffmann-La Roche

*
Mangafodipir: Egetis Therapeutics

*
Plasmalyte A: Stempeutics Research Pvt Ltd

*
Technetium Tc99m Sestamibi: Lantheus Medical Imaging

Discover more about therapies set to grab major Myocardial Infarction market share @ Myocardial Infarction Treatment Landscape [https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Myocardial Infarction Market Strengths

*
Increasing focus on the secondary preventive measure to avoid recurrent/new events, and lifestyle changes, along with the growing number of smokers and increasing cases of obesity, diabetes, hypertension, and others, are expected to foster the market growth of MI.

Myocardial Infarction Market Opportunities

*
Major cost drivers in the 7MM healthcare system are heart attacks and strokes. The volume of the MI market is incredibly large. The patient receives several therapies concurrently. The smallest patient share portion can provide pharmaceutical companies with options worth millions of dollars.

Scope of the Myocardial Infarction Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Myocardial Infarction Companies: Thrombologic ApS, Honya Medical Inc, Boehringer Ingelheim, KU Leuven, Pfizer, Mesoblast, Inc., Beijing Anzhen Hospital, TargeGen, GlaxoSmithKline, Stiftung Institut fuer Herzinfarktforschung, Novartis, Mitsubishi Tanabe Pharma Corporation, Bayer, KAI Pharmaceuticals, Rambam Health Care Campus, Quantum Genomics SA, Hoffmann-La Roche, Egetis Therapeutics, Stempeutics Research Pvt Ltd, Lantheus Medical Imaging, and others

*
Key Myocardial Infarction Therapies: Ilomedin, MiSaver Registered , BI 765845, Empagliflozin, Tenecteplase, Eplerenone, Prochymal Registered , Shenfu Injection, TG100-115, Abciximab, Clopidogrel (Iscover/Plavix), Aliskiren, MCC-135, Fulacimstat (BAY1142524), KAI-9803, Atorvastatin, Ramipril, RO4905417, Mangafodipir, Plasmalyte A, Technetium Tc99m Sestamibi, and others

*
Myocardial Infarction Therapeutic Assessment: Myocardial Infarction current marketed and Myocardial Infarction emerging therapies

*
Myocardial Infarction Market Dynamics: Myocardial Infarction market drivers and Myocardial Infarction market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Myocardial Infarction Unmet Needs, KOL's views, Analyst's views, Myocardial Infarction Market Access and Reimbursement

To know more about Myocardial Infarction companies working in the treatment market, visit @ Myocardial Infarction Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Myocardial Infarction Market Report Introduction

2. Executive Summary for Myocardial Infarction

3. SWOT analysis of Myocardial Infarction

4. Myocardial Infarction Patient Share (%) Overview at a Glance

5. Myocardial Infarction Market Overview at a Glance

6. Myocardial Infarction Disease Background and Overview

7. Myocardial Infarction Epidemiology and Patient Population

8. Country-Specific Patient Population of Myocardial Infarction

9. Myocardial Infarction Current Treatment and Medical Practices

10. Myocardial Infarction Unmet Needs

11. Myocardial Infarction Emerging Therapies

12. Myocardial Infarction Market Outlook

13. Country-Wise Myocardial Infarction Market Analysis (2020-2034)

14. Myocardial Infarction Market Access and Reimbursement of Therapies

15. Myocardial Infarction Market Drivers

16. Myocardial Infarction Market Barriers

17. Myocardial Infarction Appendix

18. Myocardial Infarction Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myocardial-infarction-market-size-was-usd-217-billion-in-2023-to-grow-in-coming-years-20242034-analysis-by-delveinsight-pfizer-mitsubishi-tanabe-pharma-bayer-kai-pharma-egetis-therapeutics]
Phone: 14699457679
Address:304 S. Jones Blvd #2432 Las Vegas NV 89107
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services



This release was published on openPR.